Clinical Trials Logo

Fallopian Tube Carcinosarcoma clinical trials

View clinical trials related to Fallopian Tube Carcinosarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02364713 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Start date: March 13, 2015
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

NCT ID: NCT02020707 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Start date: February 24, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable), cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow tumor growth by blocking the growth of new blood vessels necessary for tumor growth. Giving nab paclitaxel and bevacizumab may kill more tumor cells than nab-paclitaxel alone.